Real-world treatment satisfaction with erenumab in migraine: analysis of the US National Health and Wellness Survey

References

• Hazard E, Munakata J, Bigal ME, et al. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value Health. 2009;12(1):55–64.
   PubMed Web of Science ®Google Scholar
• Rizzoli P, Mullally WJ. Headache. Am J Med. 2018;131(1):17–24.
   PubMed Web of Science ®Google Scholar
• Agosti R. Migraine burden of disease: from the patient’s experience to a Socio-Economic view. Headache. 2018;58:17–32.
   PubMed Web of Science ®Google Scholar
• Vo P, Fang J, Bilitou A, et al. Patients’ perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain. 2018;19(1):82.
   PubMed Web of Science ®Google Scholar
• Ong JJY, de Felice M. Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics. 2018;15(2):274–290.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71(8):559–566.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644–655.
   PubMed Web of Science ®Google Scholar
• Bonafede M, Wilson K, Xue F. Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. Cephalalgia. 2019;39(9):1086–1098.
   PubMed Web of Science ®Google Scholar
• Clark M, Schwedt T, Tepper S, et al. Patient satisfaction with prophylactic migraine medications. Headache. 2017;57:133.
   Web of Science ®Google Scholar
• Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22–33.
   PubMed Web of Science ®Google Scholar
• Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470–485.
   PubMed Web of Science ®Google Scholar
• Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478–488.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My migraine voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018;19(1):115.
   PubMed Web of Science ®Google Scholar
• Woolley JM, Bonafede MM, Maiese BA, et al. Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache. 2017;57(9):1399–1408.
   PubMed Web of Science ®Google Scholar
• Korolainen MA, Kurki S, Lassenius MI, et al. Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care. J Headache Pain. 2019;20(1):13.
   PubMedGoogle Scholar
• Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019;20(1):37.
   PubMedGoogle Scholar
• López‐Bravo A, Oliveros‐Cid A, Sevillano‐Orte L. Treatment satisfaction with calcitonin gene‐related peptide monoclonal antibodies as a new patient‐reported outcome measure: a real‐life experience in migraine. Acta Neuro Scandinavica. 2022;145(6):669–675.
   PubMed Web of Science ®Google Scholar
• Aimovig prescribing information. 2018 [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf
   Google Scholar
• Barbanti P, Aurilia C, Egeo G, et al. Erenumab: from scientific evidence to clinical practice—the first Italian real-life data. Neurol Sci. 2019;40(S1):177–179.
   PubMedGoogle Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–1037.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–2132.
   PubMed Web of Science ®Google Scholar
• Lambru G, Hill B, Murphy M, et al. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21(1):61.
   PubMed Web of Science ®Google Scholar
• Ornello R, Casalena A, Frattale I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):32.
   PubMed Web of Science ®Google Scholar
• Raffaelli B, Kalantzis R, Mecklenburg J, et al. Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol. 2020;11:417.
   PubMed Web of Science ®Google Scholar
• Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280–2287.
   PubMed Web of Science ®Google Scholar
• Russo A, Silvestro M, di Clemente S, F, et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 2020;21(1):69.
   PubMed Web of Science ®Google Scholar
• Scheffler A, Messel O, Wurthmann S, et al. Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain. 2020;21(1):84.
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434.
   PubMed Web of Science ®Google Scholar
• Straube A, Stude P, Gaul C, et al. Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany. J Headache Pain. 2021;22(1):133.
   PubMed Web of Science ®Google Scholar
• American Headache Society. The American headache society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1–18.
   PubMed Web of Science ®Google Scholar
• Volpicelli Leonard K, Robertson C, Bhowmick A, et al. Perceived treatment satisfaction and effectiveness facilitators among patients with chronic health conditions: a self-reported survey. Interact J Med Res. 2020;9(1):e13029.
   PubMed Web of Science ®Google Scholar
• Fang J, Korrer S, Johnson J, et al. Real-world trends in characteristics of migraine patients newly initiated on erenumab in the United States. Eur J Neurology. 2020;27:103–522.
   Google Scholar
• Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–349.
   PubMed Web of Science ®Google Scholar
• Faust E, Pivneva I, Betts K, et al. Treatment patterns, healthcare resource use, and outcomes of patients with chronic and episodic migraines treated with erenumab: a multicenter chart-review study. Headache. 2019;10:293–306.
   Google Scholar
• Hines D, Shah S, Multani J, et al. Erenumab prescription early view: patient characteristics, treatment patterns and medication adherence in the United States. Headache. 2019;61:199–200.
   Web of Science ®Google Scholar
• Bogdanov A, Chia V, Szekely C, et al. Early use of erenumab in US real world practice. Cephalalgia Rep. 2021;4(4):251581632110204.
   Google Scholar
• Robbins L. CGRP monoclonal antibodies for chronic migraine: year 1 of clinical use. Pract Pain Manage. 2019;19:58–62.
   Google Scholar